These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 28188841)

  • 21. Semiparametric methods for multistate survival models in randomised trials.
    Hudson HM; Lô SN; Simes RJ; Tonkin AM; Heritier S
    Stat Med; 2014 May; 33(10):1621-45. PubMed ID: 24338893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-study hierarchical modeling of stratified clinical trial data.
    Johnson B; Carlin BP; Hodges JS
    J Biopharm Stat; 1999 Nov; 9(4):617-40. PubMed ID: 10576407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The power prior: theory and applications.
    Ibrahim JG; Chen MH; Gwon Y; Chen F
    Stat Med; 2015 Dec; 34(28):3724-49. PubMed ID: 26346180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inferring Markov chains: Bayesian estimation, model comparison, entropy rate, and out-of-class modeling.
    Strelioff CC; Crutchfield JP; Hübler AW
    Phys Rev E Stat Nonlin Soft Matter Phys; 2007 Jul; 76(1 Pt 1):011106. PubMed ID: 17677409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian restoration of ion channel records using hidden Markov models.
    Rosales R; Stark JA; Fitzgerald WJ; Hladky SB
    Biophys J; 2001 Mar; 80(3):1088-103. PubMed ID: 11222275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian method for construction of Markov models to describe dynamics on various time-scales.
    Rains EK; Andersen HC
    J Chem Phys; 2010 Oct; 133(14):144113. PubMed ID: 20949993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple imputation under Bayesianly smoothed pattern-mixture models for non-ignorable drop-out.
    Demirtas H
    Stat Med; 2005 Aug; 24(15):2345-63. PubMed ID: 15977286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bayesian random-effects markov model for tumor progression in women with a family history of breast cancer.
    Hui-Min Wu G; Chang SH; Hsiu-Hsi Chen T
    Biometrics; 2008 Dec; 64(4):1231-7. PubMed ID: 18218063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian experimental design for models with intractable likelihoods.
    Drovandi CC; Pettitt AN
    Biometrics; 2013 Dec; 69(4):937-48. PubMed ID: 24131221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian population finding with biomarkers in a randomized clinical trial.
    Morita S; Müller P
    Biometrics; 2017 Dec; 73(4):1355-1365. PubMed ID: 28257141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the Bayesian dynamic survival model in medicine.
    He J; McGee DL; Niu X
    Stat Med; 2010 Feb; 29(3):347-60. PubMed ID: 20014356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian population modeling of drug dosing adherence.
    Fellows K; Stoneking CJ; Ramanathan M
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):515-25. PubMed ID: 26319548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical Bayesian guidelines for phase IIB clinical trials.
    Thall PF; Simon R
    Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts.
    Kaciroti NA; Schork MA; Raghunathan T; Julius S
    Stat Med; 2009 Feb; 28(4):572-85. PubMed ID: 19072769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.